clinical trial · NCT07317934
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Innostellar Biotherapeutics Co.,Ltd·phase3·recruiting·n = 388
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMDLX102Aflibercept
brief summary
This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.
started
Jan 14, 2026
primary completion
Mar 1, 2028
completion
Jun 4, 2032
last updated
Aug 6, 2026
official title
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol